197 related articles for article (PubMed ID: 2526152)
1. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
[TBL] [Abstract][Full Text] [Related]
2. Calcium homeostasis, bone metabolism and safety aspects during long-term treatment with a GnRH agonist.
Eckstein N; Foldes J; Feinstein Y; Vagman I; Eshel A; Steinberg R; Statter M; Limor R; Ayalon D
Maturitas; 1992 Aug; 15(1):25-32. PubMed ID: 1388219
[TBL] [Abstract][Full Text] [Related]
3. Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3.
Scharla SH; Minne HW; Waibel-Treber S; Schaible A; Lempert UG; Wüster C; Leyendecker G; Ziegler R
J Clin Endocrinol Metab; 1990 Apr; 70(4):1055-61. PubMed ID: 2138629
[TBL] [Abstract][Full Text] [Related]
4. Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6-GnRH.
van Leusden HA; Dogterom AA
Gynecol Endocrinol; 1988 Mar; 2(1):45-51. PubMed ID: 2972173
[TBL] [Abstract][Full Text] [Related]
5. Effect of treatment with GnRH agonists on new markers of bone metabolism.
Kukuvitis A; Bildiris J; Prapas Y; Tsamis D; Papadimas J; Dimitriadou A; Vlassis G
Gynecol Obstet Invest; 1999; 47(3):194-6. PubMed ID: 10087416
[TBL] [Abstract][Full Text] [Related]
6. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.
van der Spuy ZM; Wood M; Fieggen G; Hendricks MS
S Afr Med J; 1993 Jul; 83(7):510-3. PubMed ID: 8211493
[TBL] [Abstract][Full Text] [Related]
7. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
Cheng YM; Chou CY; Huang SC; Lin HC
BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
[TBL] [Abstract][Full Text] [Related]
9. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl).
Lindsay PC; Shaw RW; Bennink HJ; Kicovic P
Fertil Steril; 1996 Feb; 65(2):342-8. PubMed ID: 8566259
[TBL] [Abstract][Full Text] [Related]
10. GnRH agonists-antagonists--clinical applications.
Shaw RW
Eur J Obstet Gynecol Reprod Biol; 1988 Jun; 28(2):109-16. PubMed ID: 2969835
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
Palomba S; Orio F; Morelli M; Russo T; Pellicano M; Nappi C; Mastrantonio P; Lombardi G; Colao A; Zullo F
J Clin Endocrinol Metab; 2002 Oct; 87(10):4476-81. PubMed ID: 12364422
[TBL] [Abstract][Full Text] [Related]
12. The GnRH agonists in the treatment of uterine leiomyomas.
Bianchi S; Fedele L
Acta Eur Fertil; 1989; 20(1):5-10. PubMed ID: 2675524
[TBL] [Abstract][Full Text] [Related]
13. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
Taga M; Minaguchi H
Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
[TBL] [Abstract][Full Text] [Related]
14. [GnRH-analogs in the therapy of uterine myomatosis].
Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.
Finkelstein JS; Klibanski A; Schaefer EH; Hornstein MD; Schiff I; Neer RM
N Engl J Med; 1994 Dec; 331(24):1618-23. PubMed ID: 7969342
[TBL] [Abstract][Full Text] [Related]
16. [Clinical application of luteinizing hormone releasing hormone agonist and its impact on bone metabolism].
Zhang M; He Y; Cao S
Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):398-401. PubMed ID: 7587574
[TBL] [Abstract][Full Text] [Related]
17. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
[TBL] [Abstract][Full Text] [Related]
18. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
[TBL] [Abstract][Full Text] [Related]
19. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
Marshall LA; Cain DF; Dmowski WP; Chesnut CH
Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
[TBL] [Abstract][Full Text] [Related]
20. Calcium metabolism in premenopausal women treated by a Gn-RH agonist for uterine myoma.
Ito M; Sakoda Y; Okamura H
Endocrinol Jpn; 1990 Dec; 37(6):907-13. PubMed ID: 1966283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
